Assessment of Dermatologic Family Impact Scale in the Parents of Children With Psoriasis

NCT02796014 | Completed

• 1 other identifier: 2016/0118
• Study Type: observational
• Target: 129
• Locations: 1 country
• Sites: 7

Brief Summary

The Dermatological Diseases Family Impact Scale (DeFIS) was developed to assess different aspects of health-related quality of life in the relatives of the patients with various skin diseases. The preliminary validation of this instrument was performed for the Turkish population. In the pilot study, this 15-item-questionnaire was shown to be easy to complete and score, and reliably help to evaluate the family members' quality of life. Psoriasis is a chronic disease which can be expected to have a significant impact on the quality of life of the patients and parents/family members alike. In line with this assumption, previous studies demonstrated that psoriasis psychosocially affects not only the patients, but also their close relatives. The psoriasis family index has been developed in an effort to objectively measure the health-related quality of life of the family members of patients with psoriasis. Nevertheless, data regarding the health-related quality of life of the parents of pediatric patients with psoriasis in the Turkish population are relatively scarce. In study, the investigators primarily aim to utilize DeFIS to assess the impact of childhood psoriasis on the quality of life of the patients' parents. Further, the investigators attempt to investigate the relation between the quality of life of the patients and their parents, and reveal disease characteristics which might influence the quality of life.

Conditions

Psoriasis; Quality of Life

Outcome Measures

Primary Outcomes (1)

• Assessment of the impact of childhood psoriasis on the parents of the patients using the Dermatological Diseases Family Impact Scale

  6 months

Secondary Outcomes (2)

• Comparison of the quality of life of the parents (as evaluated using the Dermatological Diseases Family Impact Scale) with the quality of life of the patients (as assessed using the Children's Dermatology Life Quality Index)

  6 months

• Delineating disease characteristics which influence the patients' and/or their parents' health-related quality of life

  6 months

Eligibility Criteria

• Age: 3 Months - 18 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Probability Sample

Study Population

Patients clinically (andif necessary histopathologically) diagnosed with psoriasis \< 18 years of age

You may qualify if:

• Pediatric patients diagnosed with psoriasis by the dermatologists within the study period

You may not qualify if:

• Patients with an equivocal diagnosis
• Parents unable to complete the questionnaire
• Patients with a serious medical disorder or in an emergency condition

Sponsors & Collaborators

• Istanbul Medeniyet University: lead
• Bakirkoy Dr. Sadi Konuk Research and Training Hospital: collaborator
• Haseki Training and Research Hospital: collaborator
• Haydarpasa Numune Training and Research Hospital: collaborator
• Istanbul Training and Research Hospital: collaborator
• Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization: collaborator
• Sisli Hamidiye Etfal Training and Research Hospital: collaborator

Study Sites (7)

Istanbul Medeniyet University Goztepe Research and Training Hospital

Istanbul, Kadikoy, 34720, Turkey (Türkiye)

Location

Bakirkoy Dr. Sadi Konuk Research and Training Hospital

Istanbul, Turkey (Türkiye)

Location

Haseki Training and Research Hospital

Istanbul, Turkey (Türkiye)

Location

Haydarpasa Numune Training and Research Hospital

Istanbul, Turkey (Türkiye)

Location

Istanbul Training and Research Hospital

Istanbul, Turkey (Türkiye)

Location

Okmeydani Training and Research Hospital

Istanbul, Turkey (Türkiye)

Location

Sisli Etfal Training & Research Hospital

Istanbul, Turkey (Türkiye)

Location

Related Publications (7)

• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994 May;19(3):210-6. doi: 10.1111/j.1365-2230.1994.tb01167.x.

  PMID: 8033378 BACKGROUND

• Gurel MS, Yanik M, Simsek Z, Kati M, Karaman A. Quality of life instrument for Turkish people with skin diseases. Int J Dermatol. 2005 Nov;44(11):933-8. doi: 10.1111/j.1365-4632.2004.02225.x.

  PMID: 16336527 BACKGROUND

• Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol. 1995 Jun;132(6):942-9. doi: 10.1111/j.1365-2133.1995.tb16953.x.

  PMID: 7662573 BACKGROUND

• Basra MK, Sue-Ho R, Finlay AY. The Family Dermatology Life Quality Index: measuring the secondary impact of skin disease. Br J Dermatol. 2007 Mar;156(3):528-38. doi: 10.1111/j.1365-2133.2006.07617.x.

  PMID: 17300244 BACKGROUND

• Eghlileb AM, Basra MK, Finlay AY. The psoriasis family index: preliminary results of validation of a quality of life instrument for family members of patients with psoriasis. Dermatology. 2009;219(1):63-70. doi: 10.1159/000209234. Epub 2009 Mar 13.

  PMID: 19295185 BACKGROUND

• Tadros A, Vergou T, Stratigos AJ, Tzavara C, Hletsos M, Katsambas A, Antoniou C. Psoriasis: is it the tip of the iceberg for the quality of life of patients and their families? J Eur Acad Dermatol Venereol. 2011 Nov;25(11):1282-7. doi: 10.1111/j.1468-3083.2010.03965.x. Epub 2011 Jan 17.

  PMID: 21241373 BACKGROUND

• Ganemo A, Wahlgren CF, Svensson A. Quality of life and clinical features in Swedish children with psoriasis. Pediatr Dermatol. 2011 Jul-Aug;28(4):375-9. doi: 10.1111/j.1525-1470.2010.01292.x. Epub 2011 Jul 8.

  PMID: 21736605 BACKGROUND

Related Links

• Development and preliminary validation of the dermatological family impact scale

MeSH Terms

Conditions

Psoriasis

Condition Hierarchy (Ancestors)

Skin Diseases, Papulosquamous; Skin Diseases; Skin and Connective Tissue Diseases

Study Officials

• Burak Tekin, M.D.

  Istanbul Medeniyet University Goztepe Research and Training Hospital Department of Dermatology

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Dr, M.D.

Study Record Dates

• First Submitted: June 7, 2016
• First Posted: June 10, 2016
• Study Start: May 1, 2016
• Primary Completion: March 1, 2017
• Study Completion: March 1, 2017
• Last Updated: August 21, 2017

Record last verified: 2017-08

Locations

TU (7)